Prothrombin Fragment 1+2, Thrombin- Antithrombin III-Complexes and Fibrinopeptide A in Spontaneously Clotting Whole Blood In Vitro

Summary

Previous in vitro studies using spontaneously clotting whole blood revealed thrombin formation and high fibrinopeptide A (FPA) concentrations measured during incubation time. This occurred in spite of normal concentrations of thrombin antagonists present in the blood of the healthy subjects examined. However, there are several reports showing that in vivo increased thrombin- anti thrombin III-complex (TAT) concentrations and relatively low FPA concentrations may occur e. g. in patients with (pre)thrombotic disorders. These in vivo findings indicate more effective thrombin inhibition by antithrombin III, with almost no fibrin formation. To find an explanation for the differences observed in vitro and in vivo, we extended the in vitro studies by measuring concentrations of prothrombin fragment 1 + 2 (F_{1 + 2}), TAT and FPA at several time points until 30 min. Our goal was to test whether thrombin at least initially is neutralized by antithrombin III, resulting in a lack of fibrin formation, either in the absence or in the presence of heparin (0.2 and 0.5 U/ml whole blood, respectively).

In the absence of heparin a simultaneous increase in the concentrations of F₁₊₂, TAT and FPA was observed. Thrombin was only partially neutralized by antithrombin III and large amounts of fibrin were formed. The addition of heparin virtually suppressed thrombin formation since the F_{1 + 2} concentration remained low. Moreover, the small amounts of thrombin formed were neutralized by antithrombin III to a greater extent than in the absence of heparin. Thus, in the presence of heparin less fibrin was produced as evidenced by significantly lower FPA concentrations.

Experiments using blood of two patients with antithrombin III deficiency showed that fibrin formation was not different from the healthy controls in spite of the significantly higher initial F_{1 + 2} concentration measured. During incubation, the patients tended to form more thrombin, of which proportionally less was neutralized by antithrombin III, and more fibrin as compared to the healthy controls. Heparin addition suppressed thrombin formation less efficiently.

• References

• 1 Lorenz R, Gebhart S, Heptner W, Classen M. In vitro studies of secretion of platelet factor 4 and generation of fibrinopeptid A in native whole blood. Thromb Res 1988; 50: 231-5
• 2 Kaplan KL, Drillings M, Lesznik G. Fibrinopeptide A cleavage and platelet release in whole blood in vitro. J Clin Invest 1981; 67: 1561-8
• 3 Prowse CV, Vigano S, Borsey DQ, Dawes J. The release of beta-thromboglobulin from platelets during the clotting of whole blood. Thromb Res 1980; 17: 433-42
• 4 Shuman MA, Levine SP. Thrombin generation and secretion of platelet factor 4 during blood clotting. J Clin Invest 1978; 61: 1102-6
• 5 Rybak ME, Lau HK, Tomkins B, Rosenberg RD. Relationship between platelet secretion and prothrombin cleavage in native whole blood. J Clin Invest 1981; 68: 405-12
• 6 Shuman MA, Levine SP. Relationship between secretion of platelet factor 4 and thrombin generation during in vitro blood clotting. J Clin Invest 1980; 65: 307-13
• 7 Estivals M, Pelzer H, Sie P, Pichon J, Boccalon H, Boneu B. Prothrombin fragment 1 + 2, thrombin-antithrombin III complexes and D-dimers in acute deep vein thrombosis: effects of heparin treatment. Br J Haematol 1991; 78: 421-4
• 8 Yudelman IM, Nossel HL, Kaplan KL, Hirsh J. Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. Blood 1978; 51: 1189-95
• 9 Bartsch P, Haeberli A, Straub PW. Blood coagulation after long distance running: Antithrombin III prevents fibrin formation. Thromb Haemost 1990; 63: 430-4
• 10 Herren T, Bartsch P, Haeberli A, Straub PW. Increased thrombin-antithrombin III complexes after one h of physical exercise. J Appl Physiol 1992; 73: 2499-504
• 11 De Boer K, Ten Cate JW, Sturk A, Borm JJ J, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989; 160: 95-100
• 12 Weiner CP, Kwaan H, Hauck WW, Duboe FJ, Paul M, Wallemark CB. Fibrin generation in normal pregnancy. Obstet Gynecol 1984; 64: 46-8
• 13 Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981; 10: 369-90
• 14 Demers C, Ginsberg J, Henderson P, Ofosu FA, Weitz JI, Blajchman MA. Measurement of markers of activated coagulation in antithrombin III deficient subjects. Thromb Haemost 1992; 67: 542-4
• 15 Schulman S, Tengborn L. Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemost 1992; 68: 634-6
• 16 Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977; ii: 581-4
• 17 Marciniak E, Farley CH, De Simone PA. Familial thrombosis due to antithrombin III deficiency. Blood 1974; 43: 219-31
• 18 Pratt CW, Church FC. Antithrombin: Structure and function. Semin Hematol 1991; 28: 3-9
• 19 Pelzer H, Schwarz A, Stiiber W. Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide. Thromb Haemostas 1991; 65: 153-9
• 20 Lau HK, Rosenberg JS, Beeler DL, Rosenberg RD. The isolation and characterization of a specific antibody population directed against the prothrombin activation fragments F₂ and F_{1 + 2} . J Biol Chem 1979; 254: 8751-61
• 21 Lau HK, Rosenberg RD. The isolation and characterization of a specific antibody population directed against the thrombin-antithrombin complex. J Biol Chem 1980; 255: 5885-93
• 22 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-6
• 23 Lollar P, Owen WG. Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. J Clin Invest 1980; 66: 1222-30
• 24 Machovich R. Choices among the possible reaction routes catalyzed by thrombin. Ann NY Acad Sci 1986; 485: 170-83
• 25 Carlson TH. Clearance of thrombin in vivo: significance of alternative pathways. Mol Cell Biochem 1986; 71: 97-105
• 26 Bourin MC, Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J 1993; 289: 313-30
• 27 Preissner KT. Anticoagulant potential of endothelial cell membrane components. Haemostasis 1988; 18: 271-306
• 28 Parker KA, Tollefsen DM. The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation. J Biol Chem 1985; 260: 3501-5
• 29 Mc Guire EA, Tollefsen DM. Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells. J Biol Chem 1987; 262: 169-75
• 30 Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties. J Clin Invest 1989; 84: 1096-104
• 31 Liu CY, Nossel HL, Kaplan KL. The binding of thrombin by fibrin. J Biol Chem 1979; 254: 10421-5
• 32 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91
• 33 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-23
• 34 De Marco L, Mazzucato M, Masotti A, Fenton II JW, Ruggeri ZM. Function of glycoprotein Iba in platelet activation induced by alphathrombin. J Biol Chem 1991; 266: 23776-83
• 35 Shuman MA. Thrombin-cellular interactions. Ann NY Acad Sci 1986; 485: 228-39
• 36 Bauer KA, Rosenberg RD. The pathophysiology of the prcthrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-50
• 37 Jesty J. The kinetics of inhibition of thrombin by antithrombin in the presence of components of the hemostatic system. Blood 1985; 66: 1189-95
• 38 Downing MR, Bloom JW, Mann KG. Comparison of the inhibition of thrombin by three plasma protease inhibitors. Biochemistry 1978; 17: 2649-53
• 39 Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74
• 40 Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-62
• 41 Ofosu FA, Sie P, Modi GJ, Fernandez F, Buchanan MR, Blajchman MA, Boneu B, Hirsh J. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J 1987; 243: 579-88
• 42 Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-96
• 43 Zucker MB, Katz IR. Platelet factor 4: Production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med 1991; 198: 693-702
• 44 Bauer KA, Goodman TL, Kass BL, Rosenberg RD. Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin III deficiency. J Clin Invest 1985; 76: 826-36
• 45 Nossel HL, Yudelman I, Canfield RE, Butler Jr VP, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53
• 46 Marcum JA, Mc Kenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparin-like molecules bound to the endothelium. J Clin Invest 1984; 74: 341-50
• 47 Ofosu FA, Modi GJ, Hirsh J, Buchanan MR, Blajchman MA. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides. Ann NY Acad Sci 1986; 485: 41-55
• 48 Mitchell L, Piovella F, Ofosu F, Andrew M. α₂-Macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children. Blood 1991; 78: 2299-304